MoCA© Development Team Collaborators:
    Dr Howard Chertkow MD FRCP (C)
    McGill University Canada

    Dr Natalie Phillips PhD
    Concordia University Canada

Collaborators who provide valuable input and advice:
    Dr Valérie Bédirian PhD
    University of Montreal Canada

    Dr Jeffrey L. Cummings MD
    Cleveland Clinic, Las Vegas USA

    Dr Glen R. Finney MD
    University of Florida USA

    Dr Serge Gauthier MD FRCP (C)
    McGill University Canada

MoCA© ACE Study:
    Montreal Cognitive Assessment (MoCA©) Normative Data for Age, Culture and Education.
    Variables:
        This study aims to provide freely accessible normative data for the MoCA© across ages, education
        levels, in 10 languages and cultures.
        Well-validated, reliable, freely accessible normative data for the MoCA© will be an invaluable aid
        to help clinicians around the world detect and diagnose early and efficiently various causes of
        cognitive impairment across various ages and education levels. The normative data will also help
        researchers assess various cognitive therapies and outcome predictors, and will allow international
        collaboration when using a common well-validated and normed cognitive screening tool. Through
        this study, official, comparable, well-normed versions of the MoCA© will be made available in 10
        languages/dialects.
        This study is in the planning stage. Interested investigators are invited to contact Dr Ziad Nasreddine
        for more information at info@mocatest.org

ADNI 2 to include testing with the MoCA©:
    The Alzheimer's Disease Neuroimaging Initiative (ADNI) is currently into its extension (ADNI-Go) and
    will be starting its second phase (ADNI 2) next year. The MoCA© will be administered as part of
    ADNI 2, with data gathered on a large set of early and late MCI individuals, normals, and AD
    research subjects. This will provide a large dataset for future research.

MoCA© Alternate Versions:
    To decrease possible learning effects when the MoCA is administered repetitively, four alternative
    MoCA© forms are in development. Two versions in English (validation study completed) will be
    shortly posted on the MoCA© website, and two French alternate versions are undergoing validation.
    Phillips N. et al. Validation of alternate forms for the Montreal Cognitive Assessment (MoCA©) will
    be presented at the 39th International Neuropsychological Society Meeting in Boston February 2-5,
    2011.

MoCA© in Low Education:
    To better adjust the MoCA for lower educated subjects, 2 points should be added to the total
    MoCA© score for subjects with 4-9 years of education, 1 point for 10-12 years of education.
    Johns E.K. et al. Level of education and performance on the Montreal Cognitive Assessment
    (MoCA©): New recommendations for education corrections. Presented at the Cognitive Aging
    Conference 2010, Atlanta, Georgia, April 15-18th, 2010.
    Johns E.K. et al. The Montreal Cognitive Assessment (MoCA©): Normative Data in the Community.
    The Canadian Journal of Geriatrics 2008, 11 (1), 62. Abstract.

MoCA© for the Blind:
    A version of the MoCA© without the visual elements has been validated for the blind.
    Wittich W et al. Sensitivity and specificity of the Montreal Cognitive Assessment modified for
    individuals who are visually impaired. Journal of Visual Impairment & Blindness, 104(6), 360-368,
    June 2010.

MoCA© is recommended by NIH and Canadian Stroke Consortium for Cognitive Assessment after
Stroke.

Because it contains subtests with executive function as well as memory, the MoCA© is ideal for
assessing Vascular Dementia and Vascular Cognitive Impairment (VCI) which may have significant frontal
lobe pathology. A workshop group of NIH and Canadian Stroke Consortium has suggested a brief
method of assessment of cognition in VCI/Vascular Dementia, which largely relies on components of the
MoCA©.
Hachinski et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network
vascular cognitive impairment harmonization standards. Stroke 2006, Sep;37(9):2220-41.